Results 231 to 240 of about 30,146 (272)

Role of ruxolitinib in preventing cardiac arrhythmias: A pooled analysis of clinical studies in hematology. [PDF]

Int J Cardiol Heart Vasc
Zaoli S, Khatri M, Holzhauer B, Peyrard S, Ferreira A, Stefanelli T.   +5 more
europepmc   +1 more source

Towards New Strategies: Case Report and Review of the Literature-Effective Use of JAK Inhibitor Baricitinib in a 4-Year-Old Boy with Anti-MDA5 Antibody-Positive Juvenile Dermatomyositis. [PDF]

J Clin Med
Buzoianu O, Satirer Ö, Kuemmerle-Deschner JB, Reiser C.   +3 more
europepmc   +1 more source

Clinical and disease characteristics from REVEAL at time of enrollment (baseline): Prospective observational study of patients with polycythemia vera in the United States [PDF]

, 2018
Boccia, Ralph V, Colucci, Philomena, Grunwald, Michael R, Mesa, Ruben, Oh, Stephen T, Paranagama, Dilan, Parasuraman, Shreekant, Stein, Brady L   +7 more
core   +1 more source

Treatment of EPOR-rearranged acute lymphoblastic leukemia with ruxolitinib: case reports and review of the literature. [PDF]

Ann Hematol
Dai Y, Ai Y, Sun S, Tang M, Li J, Gao J, Jiang M.   +6 more
europepmc   +1 more source

Reversal of third-degree AV block with ruxolitinib in VEXAS-associated myocarditis: a case report. [PDF]

Eur Heart J Case Rep
Younas S, Van Beveren J, Bogaert J, Beckers M, Ector J.   +4 more
europepmc   +1 more source

Treatment of vitiligo with topical ruxolitinib: a narrative review. [PDF]

Drugs Context
Monteiro E Silva G, Mohamed A, Ferreira C, Torres T.   +3 more
europepmc   +1 more source

Combinatorial BCL2/BCL2L1 expression predicts clinical response to ruxolitinib in myelofibrosis. [PDF]

Biomark Res
Coltro G, Videschi V, Gesullo F, Violi F, Balliu M, Vannucchi AM, Guglielmelli P.   +6 more
europepmc   +1 more source

Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting dose: Analysis of AIFA registries. [PDF]

Ann Hematol
Breccia M, Celant S, Palandri F, Passamonti F, Olimpieri PP, Summa V, Guarcello A, Palumbo GA, Pane F, Guglielmelli P, Zinzani P, Corradini P, Russo P.   +12 more
europepmc   +1 more source

Topical 1.5% ruxolitinib cream for facial refractory segmental vitiligo: A retrospective single-center study. [PDF]

JAAD Int
Huang H, Duan D, Huang H, Tang X, Zhu C, Zhang Y, Li M, Sheng Y, Xiang L, Cui Y, Zhou Y, Zhang X, Zhang B.   +12 more
europepmc   +1 more source

Ruxolitinib: a targeted treatment option for patients with polycythemia vera

, 2016
Kris Vaddi, Srđan Verstovšek, Kiladjian JJ   +2 more
openalex   +1 more source